WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy

Purpose: WRN promoter CpG island hypermethylation in colorectal cancer has been reported to increase sensitivity to irinotecan-based therapies. We aimed to characterize methylation of the WRN promoter, determine the effect of WRN promoter hypermethylation upon expression, and validate a previous report that WRN promoter hypermethylation predicts improved outcomes for patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based therapy. Experimental Design: WRN methylation status was assessed using methylation-specific PCR and bisulfite sequencing assays. WRN expression was determined using qRT-PCR and Western blotting. WRN methylation status was correlated with overall survival (OS) and progression-free survival (PFS) in 183 patients with mCRC. Among these patients, 90 received capecitabine monotherapy as first-line therapy, and 93 received capecitabine plus irinotecan (CAPIRI) therapy as part of the CAIRO phase III clinical trial. Results: WRN mRNA and WRN protein expression levels were low in colorectal cancer cell lines and in primary colorectal cancer and were largely independent of WRN methylation status. Patients with methylated WRN colorectal cancer had a shorter OS compared with patients who had unmethylated WRN colorectal cancer (HR = 1.6; 95% confidence interval [CI], 1.2–2.2; P = 0.003). Patients with unmethylated WRN showed a significantly longer PFS when treated with CAPIRI compared with capecitabine alone (HR = 0.48; 95% CI, 0.32–0.70; P = 0.0001). In contrast, patients did not benefit from adding irinotecan to capecitabine when WRN was methylated (HR = 1.1; 95% CI, 0.69–1.77; P = 0.7). Conclusions: WRN expression is largely independent of WRN promoter hypermethylation in colorectal cancer. Moreover, we could not validate the previous finding that WRN promoter hypermethylation predicts improved clinical outcomes of mCRC treated with irinotecan-based therapy and found instead the opposite result. Clin Cancer Res; 22(18); 4612–22. ©2016 AACR.

[1]  R. Monnat,et al.  Human RECQ helicases: roles in cancer, aging, and inherited disease , 2014 .

[2]  I. Nagtegaal,et al.  Genomic landscape of metastatic colorectal cancer , 2014, Nature Communications.

[3]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[4]  V. Bohr,et al.  Human RecQ helicases in DNA repair, recombination, and replication. , 2014, Annual review of biochemistry.

[5]  I. Nagtegaal,et al.  Chromosomal Copy Number Aberrations in Colorectal Metastases Resemble Their Primary Counterparts and Differences Are Typically Non-Recurrent , 2014, PloS one.

[6]  Hanlee P. Ji,et al.  Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis , 2013, BMC Medical Genomics.

[7]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[8]  D. Aoki,et al.  Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells , 2012, Oncology reports.

[9]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[10]  I. Nagtegaal,et al.  Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. , 2012, European journal of cancer.

[11]  William M. Grady,et al.  Epigenetics and colorectal cancer , 2011, Nature Reviews Gastroenterology &Hepatology.

[12]  J. Ellenberg,et al.  The quantitative proteome of a human cell line , 2011, Molecular systems biology.

[13]  Martin Kircher,et al.  Deep proteome and transcriptome mapping of a human cancer cell line , 2011, Molecular systems biology.

[14]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[15]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[16]  I. Nagtegaal,et al.  KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.

[17]  M. Emond,et al.  The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage. , 2010, Cancer research.

[18]  C. Punt,et al.  Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. , 2010, Clinical therapeutics.

[19]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[20]  C. Punt,et al.  Chemotherapy, which drugs and when. , 2009, European journal of cancer.

[21]  I. Nagtegaal,et al.  A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? , 2009, European journal of cancer.

[22]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[23]  Hiroyuki Yamamoto,et al.  WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer , 2008, Modern Pathology.

[24]  Linda Mol,et al.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.

[25]  Jeffrey W. Clark,et al.  CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma , 2007, Virchows Archiv.

[26]  J. Herman,et al.  Promoter Methylation Precedes Chromosomal Alterations in Colorectal Cancer Development , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[27]  M. Fraga,et al.  Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Pinkel,et al.  Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas , 2005, Oncogene.

[29]  M. Paz,et al.  CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  B. Clurman,et al.  Werner syndrome protein limits MYC-induced cellular senescence. , 2003, Genes & development.

[31]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[32]  N. Ellis,et al.  Differential regulation of human RecQ family helicases in cell transformation and cell cycle , 2000, Oncogene.

[33]  R. Monnat,et al.  WRN helicase expression in Werner syndrome cell lines. , 2000, Nucleic acids research.

[34]  Jun Yokota,et al.  Sp1-Mediated Transcription of the Werner Helicase Gene Is Modulated by Rb and p53 , 1998, Molecular and Cellular Biology.

[35]  G. Steele.  Cancer: Principles and Practice of Oncology , 1983 .

[36]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.